Novo Nordisk A/S (NYSE:NVO) Trading Down 1.5% – Here’s What Happened

Novo Nordisk A/S (NYSE:NVO) shares dropped 1.5% during mid-day trading on Friday . The stock traded as low as $36.18 and last traded at $36.5060. Approximately 26,162,919 shares were traded during trading, an increase of 4% from the average daily volume of 25,118,559 shares. The stock had previously closed at $37.08.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approves higher‑dose Wegovy (semaglutide 7.2 mg, “Wegovy HD”) with strong STEP UP trial weight‑loss results (~20.7% mean weight loss); company plans a U.S. launch in April—this supports revenue and market share recovery vs. Lilly. Reuters: Novo Nordisk wins U.S. nod for higher-dose Wegovy
• Positive Sentiment: Chinese government official expressed support for Novo Nordisk’s continued presence and market cultivation in China—political goodwill could ease market access and reimbursement discussions in a major growth market. Reuters: China expresses hopes over Novo Nordisk’s presence in market
• Neutral Sentiment: Sanford C. Bernstein initiated coverage on NVO — could increase analyst attention and liquidity; impact depends on the firm’s stance and ratings (article linked). Sanford C. Bernstein Initiates Coverage on Novo Nordisk
• Neutral Sentiment: Rhythm Pharmaceuticals won an FDA approval for a rare genetic‑obesity therapy—limited overlap with Novo’s mass‑market GLP‑1 franchise, so competitive impact is minimal. Yahoo/Finance: Rhythm Grabs A New Obesity Approval
• Negative Sentiment: An FDA warning letter flagged deficiencies in Novo’s pharmacovigilance reporting for serious/unexpected adverse events for GLP‑1s (including Ozempic/Wegovy)—this raises regulatory scrutiny and potential compliance costs, which investors view negatively. Yahoo/Finance: FDA Letter Puts Novo Nordisk GLP-1 Risks And Valuation In Focus
• Negative Sentiment: Patent expiry for semaglutide in India opens the market to low‑cost generics (reports of Ozempic copies selling for ~$14) — this threatens international pricing and volume, particularly in large emerging markets. Financial Post: Ozempic Copies to Cost $14 in India
• Negative Sentiment: Competitive pressure from Eli Lilly’s next‑gen agents (retatrutide) and positive data for rivals are keeping investor concerns about market share and pricing intensity elevated. ProactiveInvestors: Lilly GLP-1 trial data and concerns
• Negative Sentiment: Semaglutide failed to show benefit in early Alzheimer’s at AD/PD 2026—this is a setback for potential label expansion beyond metabolic indications and reduces upside from new indications. Yahoo News: AD/PD 2026: semaglutide fails in early Alzheimer’s

Wall Street Analysts Forecast Growth

NVO has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. CICC Research began coverage on Novo Nordisk A/S in a report on Friday, January 9th. They issued an “outperform” rating and a $73.50 price objective for the company. BMO Capital Markets reissued a “market perform” rating on shares of Novo Nordisk A/S in a research note on Thursday, February 5th. The Goldman Sachs Group restated a “neutral” rating and set a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday, March 2nd. Finally, TD Cowen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price target on the stock. in a research report on Tuesday, March 10th. Four investment analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $65.56.

Novo Nordisk A/S Trading Down 1.5%

The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The business has a 50-day simple moving average of $48.22 and a two-hundred day simple moving average of $51.11. The stock has a market cap of $163.00 billion, a price-to-earnings ratio of 10.52 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The company had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. Equities analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The firm also recently declared a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be issued a dividend of $1.2751 per share. The ex-dividend date of this dividend is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 23.63%.

Hedge Funds Weigh In On Novo Nordisk A/S

Several institutional investors and hedge funds have recently modified their holdings of NVO. True Wealth Design LLC lifted its stake in shares of Novo Nordisk A/S by 209.8% during the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after buying an additional 300 shares during the last quarter. Guerra Advisors Inc acquired a new position in Novo Nordisk A/S in the 3rd quarter valued at about $25,000. Godfrey Financial Associates Inc. acquired a new position in Novo Nordisk A/S in the 4th quarter valued at about $25,000. Strengthening Families & Communities LLC bought a new position in Novo Nordisk A/S in the 3rd quarter valued at about $30,000. Finally, WealthCollab LLC lifted its position in Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after acquiring an additional 260 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.